- Firefly Neuroscience (AIFF, Financial) to be added to Russell Microcap® Index effective June 30, 2025.
- The company has achieved FDA clearance for its BNA Platform and joined NVIDIA Connect in 2025.
- Acquisition of Evoke Neuroscience expands Firefly's database, IP portfolio, and commercial footprint.
Firefly Neuroscience, Inc. (NASDAQ: AIFF), an Artificial Intelligence company focusing on brain health solutions, will be included in the Russell Microcap® Index as part of the June 30, 2025 reconstitution. This development is significant as Russell indexes are benchmarks for approximately $10.6 trillion in assets, providing widespread visibility among institutional and retail investors. This comes less than a year after Firefly's Nasdaq listing via a reverse merger.
The inclusion in the Russell Microcap® Index follows several key achievements for Firefly in 2025. The company discovered a cognitive brain age biomarker using their FDA-cleared BNA Platform and was accepted into the NVIDIA Connect program, highlighting their technological advancements. Additionally, Firefly expanded its database and intellectual property portfolio through the acquisition of Evoke Neuroscience, which also enhanced its commercial footprint.
CEO Greg Lipschitz emphasized the importance of these milestones, including the development of a method to distinguish between different stages of Alzheimer's disease. This not only underscores Firefly's commitment to innovative brain health solutions but also positions the company for increased investor interest and support as it continues to execute its growth strategies.
Membership in the Russell Microcap® Index will last for one year and includes automatic inclusion in the appropriate growth and value style indexes. This is anticipated to improve liquidity and potentially reduce volatility for Firefly Neuroscience, thereby enhancing its investment profile.
